Ai says no to Aoxing
This article was originally published in Scrip
Mr. Bob Yunjun Ai has resigned as Chief Financial Officer of Aoxing Pharmaceutical, the US-incorporated specialty pharma company with its operations in China, specialising in research, development, manufacturing and distribution of a variety of narcotics and pain-management products, to pursue other business interests. The company has appointed Mr. Guoan Zhang, former Senior Vice President of Finance, as acting Chief Financial. The Company also appointed Ms Guirong Zhou as Vice President of R&D to lead the R&D function.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.